Content area
Full Text
[Image omitted] - (http://www.fiercebiotech.com/story/biotech-ipos-class-2014-still-rolling-investors-line-cash/2014-02-14) The most likely indicator of whether biotech's Wall Street hot streak can last is whether investors are getting good returns on all these drug developer IPOs. And so far, the beneficiaries of 2014's boomlet are coming through.
In total, the 18 life sciences companies that have gone public this year are up 34.7% above their initial pricings. Leading the way are Dicerna ($DRNA), which is trading at roughly 260% of its $15 debut, and Ultragenyx ($RARE), whose share value has more than doubled to about $44. Orphan drug outfit...